Why the study?
Does the addition of isosorbide dinitrate and hydralazine to conventional therapy reduce one-year mortality in black patients with heart failure?
Population
Black patients with heart failure
Comparison
Fixed-dose combination of isosorbide dinitrate… vs Conventional therapy
Design
Editorial
Follow-up
1 year
Authors
Loading...
This editorial discusses the implications of the A-HeFT trial, which demonstrated a 43% relative reduction in one-year mortality with isosorbide dinitrate and hydralazine in black patients with heart failure, raising questions about race-based therapeutics.
Does the addition of isosorbide dinitrate and hydralazine to conventional therapy reduce one-year mortality in black patients with heart failure?
This editorial discusses the implications of the A-HeFT trial, which demonstrated a 43% relative reduction in one-year mortality with isosorbide dinitrate and hydralazine in black patients with heart failure, raising questions about race-based therapeutics.
M. Gregg Bloche (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: